Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$11.16 USD

11.16
9,576,029

-0.06 (-0.53%)

Updated May 10, 2024 04:00 PM ET

After-Market: $11.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.

Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates

Viatris (VTRS) delivered earnings and revenue surprises of -1.47% and 2.12%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Viatris (VTRS)

Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.

Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Evaluate the expected performance of Viatris (VTRS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.87% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.

Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.

Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.

Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates

Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.

Viatris (VTRS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.

Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.

Insights Into Viatris (VTRS) Q4: Wall Street Projections for Key Metrics

Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 15.09% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Embecta Corp. (EMBC) Surpasses Q1 Earnings and Revenue Estimates

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 35.56% and 4.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH